nab-paclitaxel + apatinib + adebrelimab

This combination therapy consists of nab-paclitaxel, apatinib, and adebrelimab. Nab-paclitaxel is a nanoparticle albumin-bound formulation of the cytotoxic agent paclitaxel, which functions as a microtubule-stabilizing agent to inhibit cell mitosis. Apatinib is a small-molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR2), thereby exerting anti-angiogenic effects. Adebrelimab is a humanized monoclonal antibody that targets programmed cell death 1 ligand 1 (PD-L1), acting as an immune checkpoint inhibitor to restore anti-tumor immune responses. This triplet regimen is being evaluated in Phase 2 clinical trials by The First Affiliated Hospital of Xiamen University for the treatment of locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma in patients who have previously progressed on immunotherapy.

Brand names

Airuika

Other names

Paclitaxel (Albumin-bound) + Apatinib + Adebrelimabnab-paclitaxel + apatinib mesylate + adebrelimab